Phase 1 Clinical Trial Results for Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma (GBM) Now in Nature Communications
📢 Exciting News! The results of our Phase 1 clinical trial for Rhenium (186Re) Obisbemeda in recurrent glioblastoma (GBM) have been published in Nature Communications! This peer-reviewed study highlights the potential of our targeted radiotherapeutic to improve outcomes for GBM patients.
🔬 Key Findings:
- Demonstrated Safety & Response: Rhenium (186Re) Obisbemeda was well-tolerated and showed promising signs of efficacy.
- Extended Survival: Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall survival of 17 months—more than double the standard of care’s 8-month survival.
This publication marks a significant milestone in the development of precision radiotherapeutics for glioblastoma. As we advance to Phase 2 of the ReSPECT-GBM trial, we are actively enrolling patients to bring this innovative treatment to more individuals battling GBM.
Read the Full Publication:
🔗 Nature Communications: Read the study
📢 Press Releases: Plus Therapeutics | UT Health San Antonio
🔬 About the ReSPECT-GBM Trial: Learn more
Want to Join the ReSPECT-GBM Clinical Trial?
We are currently enrolling patients and new investigative sites.
📧 Contact us: info@plustherapeutics.com
#Glioblastoma #BrainCancer #ClinicalTrials #Radiotherapeutics #MedicalInnovation #NeuroOncology #GBM #CancerResearch
Recent Comments